Oncology
-
Merck Reports Q3 2026 Financial Results and Raises Full-Year Outlook
Merck reported $18.1 billion in Q3 2026 sales, driven by strong KEYTRUDA and WINREVAIR growth, prompting the company to raise its full-year outlook.
-
Why Breaking Up Long Hours at the Desk May Lower Breast Cancer Risk
Emerging studies link prolonged daily sitting to a higher breast cancer risk, prompting medical specialists to advise regular movement breaks.
-
A 26-Year-Old Found a Lump and Faced Skepticism. Then Came the Diagnosis
Andrea de Armas faced initial skepticism over a breast lump at age 26, leading to a cancer diagnosis just before starting physician assistant school.
-
A Breast Cancer Specialist’s Personal Journey with Stage 0 Diagnosis
After 25 years of treating breast cancer, Dr. Jennifer Litton shares how her own Stage 0 diagnosis changed her perspective on patient care and wellness.
-
New Frontiers in Oncology: Lynch Syndrome Vaccines and Glioblastoma Treatment Targets
Researchers are testing vaccines to intercept colon cancer in Lynch syndrome patients, while a new target for drug therapy shows promise against aggressive brain cancer.
-
Researchers Develop ‘Two-Headed Dragon’ Drug to Starve Cancer Cells
Researchers at UT Austin have created an experimental drug that forces cancer cells to consume excess sugar while simultaneously blocking their fat-based energy supply.
-
Medical Breakthroughs Offer New Hope for Pancreatic Cancer Patients
Recent clinical trials for a new vaccine and targeted delivery systems are showing promise in preventing and treating pancreatic cancer.
-
Cancer Research and Advocacy: From Clinical Breakthroughs to Personal Narratives
New colorectal screening guidelines and clinical trial successes highlight cancer progress alongside high-profile disclosures on pediatric treatment.
-
Global Drug Crisis and Medical Innovation: A Dual Reality in 2026
As UN reports record global drug use and synthetic threats, ASCO Breakthrough 2026 showcases life-saving strides in precision oncology and cellular therapy.
-
Advances in Prostate Cancer: AI Monitoring, Urine Diagnostics, and Generic Access
Recent clinical breakthroughs include AI-driven muscle loss tracking, a rapid urine diagnostic test, and FDA tentative approval for generic Enzalutamide.
-
UK National Screening Committee Recommends Against Widespread Prostate Cancer Screening
The UK National Screening Committee has advised against a national prostate cancer screening programme, citing potential harms of overdiagnosis, while recommending targeted screening only for high-risk BRCA2 carriers.
-
Advances in Melanoma Immunotherapy: Precision Medicine Meets Preventive Vigilance
New clinical data from the 2026 ASCO meeting highlights transformative gains in melanoma treatment via personalized vaccines and antibody therapies, even as global diagnosis rates hit record highs.
-
Advancements in Oncology: From Rare Disease Breakthroughs to Regulatory Milestones
A surge in oncology research this week highlights progress in treating ultra-rare liver cancers, FDA fast-tracking for colorectal immunotherapy, and the repurposing of hypertension medication to enhance cancer treatment efficacy.
-
New Horizons in Pancreatic Oncology: Can-Fite Moves to Phase 2b as Mitochondrial ‘Addiction’ Discovery Unveils Fatal Vulnerability
Significant clinical and biological breakthroughs are reshaping the landscape of pancreatic adenocarcinoma treatment, led by Can-Fite’s advancement of Namodenoson to Phase 2b and the discovery of a mitochondrial inflammatory pathway that fuels tumor growth.
-
Professor Richard Scolyer Shares Update Amid Health Decline
Renowned melanoma expert Professor Richard Scolyer reports his battle with glioblastoma has become ‘a bit tougher’ as he continues to advocate for experimental treatment research.